FDA-cleared AI-CVD® extracts preventive insights from routine CT—identifying hidden cardiovascular, metabolic, and skeletal risk in ~40M scans/year Houston, TX – January 12th, 2026  — HeartLung Corporation  today announced U.S. Food and Drug Administration (FDA) clearance of AI-CVD® , its flagship AI-powered quantitative imaging platform, under 510(k) K252029 , marking a major inflection point in preventive medicine and opportunistic screening. With this clearance, AI-CVD® be

Houston, TX — HeartLung AI today recognized its scientific advisors, including Robert A. Kloner, MD, PhD; Arthur Agatston, MD, FACC; Claudia Henschke, MD, PhD; and David Yankelevitz, MD, as internationally recognized pioneers whose work has helped shape modern cardiovascular prevention and lung cancer screening. As part of this leadership, HeartLung AI is highlighting a recent publication by Dr. Robert A. Kloner and colleague  featured in a companion volume to Braunwald’s Hea

Houston, TX — December 2025  — HeartLung announced today the publication of a landmark Editorial Viewpoint in JACC: Cardiovascular Imaging , led by Morteza Naghavi, MD , founder of HeartLung, urging the Centers for Medicare & Medicaid Services (CMS) to recognize coronary artery calcium (CAC) imaging as a diagnostic test  and initiate national coverage. The Viewpoint, “Coronary Artery Calcium (CAC) Imaging as a Diagnostic Test: Insurance Coverage Implications,”  represents the

Agatston 2.0 and AI-CVD unveiled in a new SCCT-hosted webcast, showcasing the next generation of calcium scoring and cardiometabolic imaging. HOUSTON, TX, UNITED STATES, November 20, 2025 / EINPresswire.com / -- The Society of Cardiovascular Computed Tomography (SCCT) and HeartLung.AI today announced the release of a new sponsored webcast, “Agatston 2.0: The next generation of calcium scoring in the era of AI-CAC and AI-CVD.” The free webcast, sponsored by HeartLung.AI , br

Hosted by Society of Cardiovascular Tomography (SCCT) Agatston 2.0: The next generation of calcium scoring in the era of AI-CAC and AI-CVD Full Video View Part 1 View Part 2 Webcast Summary Thirty years ago, the Agatston Score pioneered CT-based coronary atherosclerosis imaging. Since then, extensive evidence has established CAC as the strongest predictor of CHD events. However, two limitations have constrained its clinical utility: “Power of Zero” exceptions:  Alth

New Orleans, LA — October 21, 2025  — HeartLung Technologies today announced a record-setting presence at the upcoming American Heart Association (AHA) Scientific Sessions 2025, with nine peer-reviewed studies accepted for presentation—spotlighting breakthroughs from the company’s AI-CVD™ platform, including AI-CAC™ and novel CT-derived cardiometabolic imaging biomarkers. The work spans prediction of coronary “soft plaques”, heart failure, atrial fibrillation, COPD, non-zero

HOUSTON, TX —  The American Heart Association (AHA) has released an official Scientific Statement  in Circulation recognizing AI-enabled opportunistic detection of coronary artery calcium (CAC) on routine chest CT scans  as an emerging cornerstone for cardiovascular disease prevention . The statement, titled “Opportunistic Detection of Coronary Artery Calcium on Noncardiac Chest Computed Tomography: An Emerging Tool for Cardiovascular Disease Prevention,”  highlights the tr